| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.057 | 0.3 |